HER2 Positive Breast Cancers Recruiting Phase 2 Trials for Epirubicin (DB00445)

Also known as: HER2 Positive Breast Cancer

IndicationStatusPhase
DBCOND0066412 (HER2 Positive Breast Cancers)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02682693Denosumab as an add-on Neoadjuvant Treatment (GeparX)Treatment